![]() |
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
Sponsored by: |
Merck |
---|---|
Information provided by: | Merck |
ClinicalTrials.gov Identifier: | NCT00533611 |
The primary objective of the study is to assess the effects of MK0524A in reducing flushing associated with niacin.
Condition | Intervention | Phase |
---|---|---|
Flushing |
Drug: MK0524A, /Duration of Treatment : 4 Weeks Drug: Comparator : niacin /Duration of Treatment : 1 Weeks |
Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Tolerability and Effect of MK0524A on Niacin-Induced Acute Flushing in Lipid Clinic Patients |
Estimated Enrollment: | 300 |
Study Start Date: | April 2007 |
Study Completion Date: | August 2007 |
Ages Eligible for Study: | 18 Years to 70 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Study ID Numbers: | 2007_604 |
Study First Received: | September 19, 2007 |
Last Updated: | September 19, 2007 |
ClinicalTrials.gov Identifier: | NCT00533611 History of Changes |
Health Authority: | China: Ministry of Health |
Antimetabolites Vasodilator Agents Niacinamide Vitamin B Complex Antilipemic Agents Trace Elements Cardiovascular Agents |
Signs and Symptoms Nicotinic Acids Vitamins Flushing Micronutrients Niacin |
Antimetabolites Vasodilator Agents Vitamin B Complex Molecular Mechanisms of Pharmacological Action Growth Substances Antilipemic Agents Physiological Effects of Drugs Cardiovascular Agents |
Pharmacologic Actions Signs and Symptoms Therapeutic Uses Vitamins Flushing Micronutrients Niacin |